The North America Companion Diagnostics Market is witnessing robust growth, propelled by technological advancements and increasing adoption in precision medicine. The market size was valued at USD 2,850 Million in 2025 and is projected to reach USD 8,210 Million by 2035, growing at a CAGR of 10.8% from 2024 to 2035. This growth is driven by the rise in targeted therapies and regulatory support for companion diagnostics integration in clinical workflows.
The economic impact of tariffs on "North America Companion Diagnostics Market".
Market Growth Drivers
Growing Adoption of Precision Medicine: The increasing focus on personalized treatment regimens, especially in oncology, is heavily reliant on companion diagnostics to guide therapy decisions. Companies like Roche are leading the way with FDA-approved CDx solutions that link diagnostic testing with targeted drug therapies, streamlining both diagnosis and treatment outcomes for patients. These tailored approaches enable oncologists to prescribe drugs based on the patient’s unique genetic makeup, significantly improving the effectiveness of treatments and reducing adverse effects. As a result, healthcare providers are increasingly partnering with diagnostic companies to co-develop therapeutics and companion tests, boosting the adoption of such solutions across North America.
Regulatory Support and Rapid Approvals: The U.S. FDA’s emphasis on co-development of drugs and diagnostics, combined with expedited review programs, is accelerating the market expansion of companion diagnostics. For instance, companies such as Thermo Fisher Scientific have benefited from regulatory initiatives that prioritize and fast-track the approval of CDx intended for high-impact diseases. These supportive policies have enabled prompt market entry and higher investments in innovative diagnostic platforms, fostering a vibrant ecosystem for research and commercial launches.
Market Trends
Integration of Next-Generation Sequencing (NGS): The adoption of next-generation sequencing platforms in companion diagnostics is a rising trend, allowing for the simultaneous detection of multiple genetic mutations related to various cancers and rare diseases. Illumina, a major player, has introduced comprehensive NGS-based CDx solutions that can rapidly analyze patient genetic profiles, delivering actionable information for oncologists. The scalability of NGS technologies is facilitating their transition from research labs to routine clinical practice throughout North America.
Rise of Artificial Intelligence and Digital Pathology: There's a growing trend toward the utilization of AI and digital tools in companion diagnostics, enhancing interpretation accuracy and operational efficiency. For example, companies like Abbott are incorporating AI-based image analysis and decision-support systems into their diagnostic platforms. This not only streamlines the diagnostic process but also improves the repeatability of results, supporting large-scale adoption in both centralized and decentralized healthcare settings.
Market Opportunities
Expansion into Non-Oncology Indications: There is significant potential for companion diagnostics in disease areas beyond oncology, such as autoimmune disorders and infectious diseases. Companies like Qiagen are exploring partnerships with pharmaceutical firms to co-develop CDx for non-cancer indications, widening the market scope and addressing unmet medical needs.
Healthcare Digitization and Telemedicine: The ongoing digitization of healthcare operations and the rise of telemedicine open new avenues for remote sample collection and decentralized testing. This creates opportunities for diagnostic companies like BioMérieux to develop user-friendly, at-home companion diagnostic kits integrated with digital reporting tools.
North America Companion Diagnostics Market Revenue (2020-2035)
The chart showcases consistent growth in the North America Companion Diagnostics Market from 2020 to 2035. Beginning with USD 1,320 Million in 2020, the market demonstrates a steady upward trajectory, reaching an estimated USD 2,850 Million by 2025 and projecting substantial acceleration to USD 8,210 Million in 2035. This surge is fueled by rising demand for personalized therapies, advances in diagnostic technologies, and increasing investments by leading industry players. The growth pattern highlights the region’s proactive emphasis on precision medicine and the expanding role of CDx in clinical decision-making. The forecast signals lucrative opportunities for both established and emerging companies as new disease indications and innovative technologies are continually integrated into the market.
North America Companion Diagnostics Market Share by Region, 2025
The pie chart illustrates the regional breakdown of the North America Companion Diagnostics Market for 2025. The United States dominates with a commanding 74% share, driven by a well-established healthcare infrastructure and robust investment in diagnostics innovation. Canada follows with 19%, supported by rising government healthcare spending and widespread adoption of precision diagnostics. Mexico holds a 5% share, while the remaining 2% is collectively attributed to other smaller territories such as Bermuda and the Caribbean nations. This distribution highlights the US’s leadership role, yet also signals growing engagement and opportunities in other North American markets as precision medicine becomes more universally accessible.
Recent Developments in North America Companion Diagnostics Market
In April 2024, Roche announced the FDA approval of its new VENTANA PD-L1 (SP263) Assay as a companion diagnostic for a range of immunotherapy drugs in lung cancer treatment. This approval allows clinicians to identify eligible patients for checkpoint inhibitor therapies, further solidifying Roche’s strategic position in the market.
In May 2024, Thermo Fisher Scientific revealed a collaboration with Merck to develop a next-generation sequencing-based companion diagnostic for advanced melanoma therapies. This partnership aims to streamline patient selection for Merck’s oncology pipeline, leveraging Thermo Fisher’s Ion Torrent technology for higher throughput and accuracy.
In March 2024, Illumina launched a new AI-powered CDx solution designed for decentralized laboratories, enabling broader deployment outside major academic centers. The solution incorporates digital reporting and cloud-based analytics, increasing accessibility and efficiency for community hospitals and clinical labs throughout North America.
Press Releases